ArticleInfection and immunity1999
Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoni.
Article in Infection and immunity, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Pre-clinical studies of Schistosoma mansoni vaccines: A scoping review.PLoS neglected tropical diseases · 2025Article
- Protein-Based Adjuvants for Vaccines as Immunomodulators of the Innate and Adaptive Immune Response: Current Knowledge, Challenges, and Future Opportunities.Pharmaceutics · 2022Review
- Article
- Bacterial flagellin-a potent immunomodulatory agent.Experimental & molecular medicine · 2017Review
- Mucosal vaccine delivery: Current state and a pediatric perspective.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
- Flagellin Encoded in Gene-Based Vector Vaccines Is a Route-Dependent Immune Adjuvant.PloS one · 2016Article
- Article
- Escherichia coli flagellin stimulates pro-inflammatory immune response.World journal of microbiology & biotechnology · 2012Article
- A pilot study on developing mucosal vaccine against alveolar echinococcosis (AE) using recombinant tetraspanin 3: Vaccine efficacy and immunology.PLoS neglected tropical diseases · 2012Article
- Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD88.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- The nature and combination of subunits used in epitope-based Schistosoma japonicum vaccine formulations affect their efficacy.Parasites & vectors · 2010Article
- Flagellin as an adjuvant: cellular mechanisms and potential.Journal of immunology (Baltimore, Md. : 1950) · 2010Review
- A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice.Viral immunology · 2010Article
- Direct stimulation of tlr5+/+ CD11c+ cells is necessary for the adjuvant activity of flagellin.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.Infection and immunity · 2009Article
- Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates.Clinical and vaccine immunology : CVI · 2009Article
- Mucosal adjuvant activity of flagellin in aged mice.Mechanisms of ageing and development · 2008Article
- Effects of flagellin on innate and adaptive immunity.Immunologic research · 2005Review
- Mucosal administration of flagellin induces innate immunity in the mouse lung.Infection and immunity · 2004Article
- Host and bacterial factors affecting induction of immune responses to flagellin expressed by attenuated Salmonella vaccine strains.Infection and immunity · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schistosomiasis is the cause of a chronic debilitating disease which accounts for significant mortality and morbidity every year, especially in tropical and subtropical areas. An epitope derived from the protective surface protein 9B-Ag of Schistosoma mansoni, designated 9B peptide-1, was previously showed to be protective in mice when conjugated to bovine serum albumin and administered subcutaneously in complete Freund's adjuvant. In this work, this protective peptide was expressed in the flagellin of a Salmonella vaccine strain, and the isolated recombinant flagella were used for immunization of mice. Since during the invasion of the parasite into the host the schistosomula migrate first to the lungs, the intranasal route of administration was employed in order to halt the parasite at an early stage of the infection. Such intranasal immunization with this peptide expressed in flagellin, without the addition of adjuvants, resulted in a significant humoral response and also led to protection against challenge infection, manifested as a reduction of the worm burden by an average of 42%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.